Actavis Eyes Acquisitions In The Middle East And Niche Products In The U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
The company's new CEO, Claudio Albrecht, is gearing up for growth by looking to acquire BioPartners, a biosimlars opportunity, but also on his radar are geographic expansion in Asia and the Middle East, and development of modified-release products.
You may also be interested in...
Public Outcry Prompts Novartis To Cancel Vasella Non-Compete Deal
Novartis drops plan to pay outgoing chairman Daniel Vasella $78 million to stop him working for competitors, bowing to growing concerns in Switzerland over executive compensation.
Switzerland's Shield Therapeutics Raises $12M To Conduct Phase III Trials On Oral Iron Deficiency Product
Oral iron deficiency therapy to advance into Phase III this year on the back of $12 million fund raising for Swiss minnow, Shield Therapeutics.
Switzerland's Shield Therapeutics Raises $12M To Conduct Phase III Trials On Oral Iron Deficiency Product
Oral iron deficiency therapy to advance into Phase III this year on the back of $12 million fund raising for Swiss minnow, Shield Therapeutics.